// OVERVIEW
Curevo Vaccine is a clinical-stage biotechnology company based in Bothell, Washington, focused on developing next-generation varicella zoster virus (VZV) vaccines with improved tolerability, including its lead shingles vaccine candidate amezosvatein. The company raised ~$200M in venture funding and was acquired by Eli Lilly in a deal worth up to $1.5 billion in cash.
// RECENT MENTIONS
// SIGNALS
2 SIGNALS
01
m_and_a·Axios Pro Rata·MAY 26, 2026
“Lilly will pay up to $1.5 billion for Curevo, a Bothell, Washington-based developer of a shingles vaccine.”
02
mention·Axios Pro Rata·MAY 26, 2026
“Lilly will pay up to $1.5 billion for Curevo, a Bothell, Washington-based developer of a shingles vaccine.”
AI-extracted from podcast / newsletter / paper summaries. May contain errors.